Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis

References

• Henter JI, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol. 1991;18(1):29–33.
   PubMed Web of Science ®Google Scholar
• Tothova Z, Berliner N. Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management. J Intensive Care Med. 2015;30(7):401–412. doi: 10.1177/0885066613517076
   PubMed Web of Science ®Google Scholar
• Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163(5):1253–1259. doi: 10.1016/j.jpeds.2013.06.053
   PubMed Web of Science ®Google Scholar
• Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–492. doi: 10.1016/j.mayocp.2013.12.012
   PubMed Web of Science ®Google Scholar
• Rivière S, Galicier L, Coppo P, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127(11):1118–1125. doi: 10.1016/j.amjmed.2014.04.034
   PubMed Web of Science ®Google Scholar
• Lehmberg K, Nichols KE, Henter JI, et al. Study group on hemophagocytic lymphohistiocytosis subtypes of the histiocyte society. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015;100(8):997–1004.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Jung JM, Won CH, et al. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site. J Am Acad Dermatol. 2014;70(6):1002–1009. doi: 10.1016/j.jaad.2013.12.023
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018–6022. doi: 10.1182/blood-2011-05-354142
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005. doi: 10.1182/blood-2013-01-453233
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58–65. doi: 10.1532/IJH97.07012
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220–224. doi: 10.1002/ajh.23911
   PubMed Web of Science ®Google Scholar
• Yu JT, Wang CY, Yang Y, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529–1536. doi: 10.1007/s00277-013-1784-3
   PubMed Web of Science ®Google Scholar
• Sano H, Kobayashi R, Tanaka J, et al. Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicenter study. Br J Haematol. 2014;165(6):786–792. doi: 10.1111/bjh.12823
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Aricó M, et al. HLH-2004:Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi: 10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Collaborative Study to Evaluate the Proposed 1st WHO International.
   Google Scholar
• Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohisocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101–109. doi: 10.1002/pbc.24188
   PubMed Web of Science ®Google Scholar
• Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the histiocyte society. Med Pediatr Oncol. 1997;28(5):342–347. doi: 10.1002/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H
   PubMedGoogle Scholar
• Wang Y, Huang W, Hu L, et al. Multi-center study of combination DEP regimen as a salvage therapy for adult refractory hemopgagocytic lymphohistiocytosis. Blood. 2015;126(19):2186–2192. doi: 10.1182/blood-2015-05-644914
   PubMed Web of Science ®Google Scholar
• Celkan T, Berrak S, Kazanci E, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. Turk J Pediatr. 2009;51(3):207–213.
   PubMed Web of Science ®Google Scholar
• Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3):221–230. doi: 10.1007/BF00443367
   PubMed Web of Science ®Google Scholar
• Lehmberg K, Sprekels B, Nichols KE, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170(4):539–549. doi: 10.1111/bjh.13462
   PubMed Web of Science ®Google Scholar
• Janka GE, Lehmberg K. Hemophagocytic syndromes an update. Blood Rev. 2014;28(4):135–142. doi: 10.1016/j.blre.2014.03.002
   PubMed Web of Science ®Google Scholar
• Trottestam H, Horne A, Aricò M, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–4584. doi: 10.1182/blood-2011-06-356261
   PubMed Web of Science ®Google Scholar
• Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treatment tefractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81(1):59–61. doi: 10.1002/ajh.20462
   PubMed Web of Science ®Google Scholar
• Olin RL, Nichols KE, Naghashpour M, et al. Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis. Am J Hematol. 2008;83(9):747–749. doi: 10.1002/ajh.21236
   PubMed Web of Science ®Google Scholar
• Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemoimmunotherapeutic regimens. Br J Haematol. 2013;162(3):376–382. doi: 10.1111/bjh.12386
   PubMed Web of Science ®Google Scholar
• Fischer A, Cerf-Bensussan N, Blanche S, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986;108(2):267–270. doi: 10.1016/S0022-3476(86)81002-2
   PubMed Web of Science ®Google Scholar
• Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single(big) step. Bone Marrow Transplant. 2008;42(7):433–437. doi: 10.1038/bmt.2008.232
   PubMed Web of Science ®Google Scholar
• Baker KS, Filipovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175–180. doi: 10.1038/bmt.2008.133
   PubMed Web of Science ®Google Scholar
• Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58–65. doi: 10.1532/IJH97.07012
   PubMed Web of Science ®Google Scholar
• Wang J, Wang Y, Wu L, et al. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016;9(1):84. doi: 10.1186/s13045-016-0317-7
   PubMed Web of Science ®Google Scholar